179 related articles for article (PubMed ID: 16119980)
1. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites.
De Lott LB; Morrison C; Suster S; Cohn DE; Frankel WL
Arch Pathol Lab Med; 2005 Sep; 129(9):1100-5. PubMed ID: 16119980
[TBL] [Abstract][Full Text] [Related]
2. Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
Winn B; Tavares R; Matoso A; Noble L; Fanion J; Waldman SA; Resnick MB
Hum Pathol; 2010 Jan; 41(1):123-8. PubMed ID: 19800103
[TBL] [Abstract][Full Text] [Related]
3. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas.
Kaimaktchiev V; Terracciano L; Tornillo L; Spichtin H; Stoios D; Bundi M; Korcheva V; Mirlacher M; Loda M; Sauter G; Corless CL
Mod Pathol; 2004 Nov; 17(11):1392-9. PubMed ID: 15205684
[TBL] [Abstract][Full Text] [Related]
4. Differentiating the undifferentiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation.
Winn B; Tavares R; Fanion J; Noble L; Gao J; Sabo E; Resnick MB
Hum Pathol; 2009 Mar; 40(3):398-404. PubMed ID: 18992917
[TBL] [Abstract][Full Text] [Related]
5. Expression of the intestinal marker Cdx2 in secondary adenocarcinomas of the colorectum.
Groisman GM; Bernheim J; Halpern M; Brazowsky E; Meir A
Arch Pathol Lab Med; 2005 Jul; 129(7):920-3. PubMed ID: 15974817
[TBL] [Abstract][Full Text] [Related]
6. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody.
Bayrak R; Haltas H; Yenidunya S
Diagn Pathol; 2012 Jan; 7():9. PubMed ID: 22268990
[TBL] [Abstract][Full Text] [Related]
7. CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall.
Mazziotta RM; Borczuk AC; Powell CA; Mansukhani M
Appl Immunohistochem Mol Morphol; 2005 Mar; 13(1):55-60. PubMed ID: 15722794
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
Chu PG; Schwarz RE; Lau SK; Yen Y; Weiss LM
Am J Surg Pathol; 2005 Mar; 29(3):359-67. PubMed ID: 15725805
[TBL] [Abstract][Full Text] [Related]
9. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs.
Barbareschi M; Murer B; Colby TV; Chilosi M; Macri E; Loda M; Doglioni C
Am J Surg Pathol; 2003 Feb; 27(2):141-9. PubMed ID: 12548159
[TBL] [Abstract][Full Text] [Related]
10. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas.
Werling RW; Yaziji H; Bacchi CE; Gown AM
Am J Surg Pathol; 2003 Mar; 27(3):303-10. PubMed ID: 12604886
[TBL] [Abstract][Full Text] [Related]
11. Expression of homeodomain protein CDX2 in colorectal adenoma and adenocarcinoma.
Bakaris S; Cetinkaya A; Ezberci F; Ekerbicer H
Histol Histopathol; 2008 Sep; 23(9):1043-7. PubMed ID: 18581275
[TBL] [Abstract][Full Text] [Related]
12. Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2.
Panarelli NC; Yantiss RK; Yeh MM; Liu Y; Chen YT
Am J Clin Pathol; 2012 Aug; 138(2):211-22. PubMed ID: 22904132
[TBL] [Abstract][Full Text] [Related]
13. CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens.
Tanaka S; Saito K; Ito T; Tajima K; Mogi A; Shitara Y; Sano T; Kuwano H
Oncol Rep; 2007 Jul; 18(1):87-92. PubMed ID: 17549351
[TBL] [Abstract][Full Text] [Related]
14. Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin.
Jaffee IM; Rahmani M; Singhal MG; Younes M
Arch Pathol Lab Med; 2006 Oct; 130(10):1522-6. PubMed ID: 17090195
[TBL] [Abstract][Full Text] [Related]
15. Demonstration of CDX2 is highly antibody dependant.
Borrisholt M; Nielsen S; Vyberg M
Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):64-72. PubMed ID: 22595949
[TBL] [Abstract][Full Text] [Related]
16. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus.
Phillips RW; Frierson HF; Moskaluk CA
Am J Surg Pathol; 2003 Nov; 27(11):1442-7. PubMed ID: 14576477
[TBL] [Abstract][Full Text] [Related]
17. Re-evaluation of phenotypic expression in undifferentiated-type early gastric adenocarcinomas using mucin core protein and CDX2.
Ikarashi S; Nishikura K; Ajioka Y; Aoyagi Y
Gastric Cancer; 2013 Apr; 16(2):208-19. PubMed ID: 22829163
[TBL] [Abstract][Full Text] [Related]
18. Cdx2, cytokeratin 20, thyroid transcription factor 1, and prostate-specific antigen expression in unusual subtypes of prostate cancer.
Leite KRM; Mitteldorf CATS; Srougi M; Dall'Oglio MF; Antunes AA; Pontes J; Camara-Lopes LH
Ann Diagn Pathol; 2008 Aug; 12(4):260-266. PubMed ID: 18620992
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive evaluation of CDX2 in invasive cervical adenocarcinomas: immunopositivity in the absence of overt colorectal morphology.
Sullivan LM; Smolkin ME; Frierson HF; Galgano MT
Am J Surg Pathol; 2008 Nov; 32(11):1608-12. PubMed ID: 18753946
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotypic differences between intestinal-type and low-grade papillary sinonasal adenocarcinomas: an immunohistochemical study of 22 cases utilizing CDX2 and MUC2.
Cathro HP; Mills SE
Am J Surg Pathol; 2004 Aug; 28(8):1026-32. PubMed ID: 15252308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]